Hoth Therapeutics Inc.
05/02/2025 | Press release | Distributed by Public on 05/02/2025 06:20
Material Event (Form 8-K)
Item 8.01 Other Events.
Merveille.ai, a wholly-owned subsidiary of Hoth Therapeutics, Inc., received confirmation from the U.S. Patent and Trademark Office, acting as Receiving Office under the Patent Cooperation Treaty ("PCT"), that all prescribed fees associated with international patent application number PCT/US2025/022598 were paid in full. The application with respect to the treatment and prevention of hair loss carries a priority date of April 5, 2024. This filing supports Merveille.ai's intellectual property strategy in advancing therapeutic innovation.
Hoth Therapeutics Inc. published this content on May 02, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on May 02, 2025 at 12:21 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io